How Jaqueline’s Promise and Persistence Paid Off

5 March 2019 In Melanoma Stories

Melanoma wasn't supposed to happen to Jacqueline. Melanoma was supposed to be a disease that older, white women got, not 21-year-old African Americans. "People often think having more melanin makes them from developing melanoma. But they’re wrong,” Jacqueline says.

Read More


Fight Back Give Back with Clinical Trials

By Cody R. Barnett, MRA Director of Communications | 24 February 2019 In News, Science

When patients understand all of their options, including clinical trials, they can make informed decisions about their care. For many patients, clinical trials represent the best possible way to get access to cutting-edge treatment options.

Read More


Overcoming Targeted Therapy Resistance

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 22 February 2019 In Science, Treatment

Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.

Read More


It’s Not that Simple: Young Women and Melanoma

By Cody R. Barnett, MRA Director of Communications | 15 February 2019 In Prevention, Science

Article after article describes the ‘skyrocketing’ increases in melanoma among young women. While most are quick to point out the clear association between intentional tanning and skin cancer, few ever hint that there may be more to the story.

Read More


Doing Good in Rebecca's Name

7 February 2019 In Melanoma Stories

It was March of 2005 when Christine Garrison’s life changed forever. She received the phone call that no mother ever wants to receive. Her daughter Rebecca’s suspicious mole was, in fact, Stage 3 melanoma.

Read More


Unchartered Territory: When Should Patients Stop Immunotherapy?

By Cody R. Barnett, MRA Director of Communications | 23 January 2019 In Melanoma Stories, Science, Treatment

For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? According to Dr. Jeffrey Weber and the data he presented at the European Society for Medical Oncology (ESMO) Congress late last year, the answer is maybe not.

Read More


Unchartered Territory: When Should Patients Stop Immunotherapy?

By Cody R. Barnett, MRA Director of Communications | 23 January 2019 In Melanoma Stories, Science, Treatment

For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? In the absence of definitive data – what does indirect data tell us?

Read More


Melanoma Treatment Advances – 2018 in Review

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 18 January 2019 In Science, Treatment

2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.

Read More


From Health Scare to Transformative Change

By Cody R. Barnett, MRA Director of Communications | 16 January 2019 In Melanoma Stories

Debra Black founded the Melanoma Research Alliance in 2007 after her own diagnosis with Stage II disease earlier that year. Since then, MRA has become the largest, non-profit funder of melanoma research worldwide.

Read More


Make Your Sun Safety Habit Stick: La Roche Posay’s My Skin Track UV

By Cody R. Barnett, MRA Director of Communications | 3 January 2019 In Allies & Partnerships, Prevention

Last month’s arrival of La Roche Posay’s My Skin Track UV may be just what the doctor ordered to help people understand the danger of overexposure to ultraviolet radiation.

Read More


Login

×